Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
1991-2-8
pubmed:abstractText
The aim of this work was to develop a strategy to isolate a morphologically stable mutant of Streptomyces ambofaciens ATCC 15154 which produced high titers of spiramycin. The rationale was to grow a nitrosoguanidine-mutated population for many generations under nonselective conditions followed by two cycles of protoplast formation and regeneration. A total of 2,400 surviving colonies were then screened for spiramycin production and subsequently checked for stability. From this experiment, strain 6-37 was isolated that produced 181 mg of spiramycin per liter and only one morphological type. The parent strain (ATCC 15154) produced 107 mg of spiramycin per liter and four morphological types. Strain 6-37 was then mutated with nitrosoguanidine, and 14,000 colonies were screened for spiramycin production. From this experiment, five strains were isolated that produced titers ranging from 187 to 373 mg of spiramycin per liter. Subsequent media and time studies with these strains resulted in a fermentation that produced 1,728 mg of spiramycin per liter.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/2268160-1150538, http://linkedlifedata.com/resource/pubmed/commentcorrection/2268160-2914852, http://linkedlifedata.com/resource/pubmed/commentcorrection/2268160-3029594, http://linkedlifedata.com/resource/pubmed/commentcorrection/2268160-3060001, http://linkedlifedata.com/resource/pubmed/commentcorrection/2268160-3079185, http://linkedlifedata.com/resource/pubmed/commentcorrection/2268160-3171544, http://linkedlifedata.com/resource/pubmed/commentcorrection/2268160-3328731, http://linkedlifedata.com/resource/pubmed/commentcorrection/2268160-3547140, http://linkedlifedata.com/resource/pubmed/commentcorrection/2268160-4215549, http://linkedlifedata.com/resource/pubmed/commentcorrection/2268160-4613148, http://linkedlifedata.com/resource/pubmed/commentcorrection/2268160-6086574, http://linkedlifedata.com/resource/pubmed/commentcorrection/2268160-6299902, http://linkedlifedata.com/resource/pubmed/commentcorrection/2268160-6307966, http://linkedlifedata.com/resource/pubmed/commentcorrection/2268160-6945475, http://linkedlifedata.com/resource/pubmed/commentcorrection/2268160-7338732
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0099-2240
pubmed:author
pubmed:issnType
Print
pubmed:volume
56
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3511-4
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1990
pubmed:articleTitle
Selection of Streptomyces ambofaciens mutants that produce large quantities of spiramycin and determination of optimal conditions for spiramycin production.
pubmed:affiliation
Fermentation Products Research, Eli Lilly and Company, Indianapolis, Indiana 46285.
pubmed:publicationType
Journal Article